文献速递重症综合管理与镇静镇痛心脑血管急症

神经重症患者的静脉血栓栓塞预防:当前实践是否最佳实践

Venous Thromboembolism Prophylaxis in Neurocritical Care Patients: Are Current Practices, Best Practices?
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论神经重症患者ICU日中60.9%使用药物预防VTE、46.9%使用机械预防、12.2%无预防,指南推荐药物预防时仅26.6%ICU日符合指南。

这项回顾性队列研究纳入2014至2017年9家医院10个成人ICU的23,191例患者,其中20.0%为神经重症患者。神经重症患者药物VTE预防覆盖60.9%的ICU日,机械预防覆盖46.9%,无预防占12.2%。56%的ICU日符合指南推荐,但符合率随推荐条款(范围6-100%)和预防类型而异;指南推荐药物预防时仅26.6%的ICU日符合,推荐机械预防时80.5%符合。神经重症学会指南发布后,指南符合率整体改善2.3%的ICU日(P=0.005)。作者认为神经重症患者最佳VTE预防实践仍存在不确定性。

要点

  • 神经重症患者药物VTE预防仅覆盖60.9%的ICU日,机械预防覆盖46.9%,12.2%的ICU日无任何VTE预防。
  • 指南推荐药物预防时仅26.6%的ICU日符合,推荐机械预防时80.5%符合,总体符合率56%。
  • 指南符合率随具体推荐条款差异大(范围6-100%),预防类型与符合率相关(P=0.05)。
  • 神经重症学会指南发布后,指南符合率整体改善2.3%的ICU日(P=0.005)。
  • VTE预防类型与性别、神经系统诊断及有创神经监测相关。

适用人群与场景

  • 2014至2017年入住9家医院10个成人内科-外科及神经ICU的患者,按主要入院诊断分类为神经重症者占20.0%(23,191例中)。

研究设计与关键结果

  • 回顾性队列研究,纳入2014至2017年9家医院10个成人ICU的23,191例患者,其中20.0%为神经重症患者。
  • 神经重症患者药物VTE预防覆盖60.9%的ICU日,机械预防覆盖46.9%,无VTE预防占12.2%的ICU日。
  • VTE预防类型与性别、神经系统诊断及有创神经监测相关。
  • 56%的ICU日符合指南推荐,符合率随推荐条款(范围6-100%)和预防类型而异(P=0.05);指南推荐药物预防时符合率26.6%的ICU日,推荐机械预防时符合率80.5%的ICU日。
  • 神经重症学会指南发布后,指南符合率整体改善2.3%的ICU日(P=0.005)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为神经重症患者最佳VTE预防实践仍存在不确定性;当前实践中机械VTE预防使用普遍,而指南推荐药物VTE预防时符合率仅26.6%的ICU日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND/OBJECTIVES: Venous thromboembolism (VTE) is a leading cause of preventable, in-hospital deaths; critically ill patients have a higher risk. Effective and efficient strategies to prevent VTE exist; however, neurocritical care patients present unique challenges due to competing risk of bleeding. The objective of this study was to examine current VTE prophylaxis practices among neurocritical care patients, concordance with guideline-recommended care, and the association with clinical outcomes.

METHODS: This retrospective cohort study of patients admitted to ten adult, medical-surgical and neurological intensive care units (ICUs) in nine hospitals between 2014 and 2017 using administrative and clinical data. Neurocritical care patients were classified based on the primary admission diagnosis. Concordance with guideline-recommended care was evaluated using recommendations from recent guidelines.

RESULTS: 20.0% of 23,191 patients were classified as neurocritical care. Among neurocritical care patients, pharmacological VTE prophylaxis was administered on 60.9% of all ICU days, mechanical VTE prophylaxis on 46.9%, and no VTE prophylaxis on 12.2% of all ICU days. Type of VTE prophylaxis was associated with sex, neurological diagnosis, and invasive neurological monitoring. Fifty-six percentage of ICU days were guideline concordant but concordance varied by recommendation (range 6-100%) and by type of VTE prophylaxis recommended (p = 0.05); among patients where guidelines recommended use of pharmacologic prophylaxis, care was concordant 26.6% of ICU days, whereas for mechanical prophylaxis it was concordant 80.5% of ICU days. There was an overall improvement in guideline concordance on 2.3% of ICU days after the publication of the Society of Neurocritical Care guideline (p = 0.005).

CONCLUSIONS: Neurocritical care patients commonly receive mechanical VTE prophylaxis despite guidelines recommending the use of pharmacological VTE prophylaxis. Our findings suggest uncertainty around best VTE prophylaxis practices for neurocritical care patients remains.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Sauro KM, Soo A, Kramer A, et al. Venous Thromboembolism Prophylaxis in Neurocritical Care Patients: Are Current Practices, Best Practices? Neurocrit Care. 2019. PMID: 30276615. doi:10.1007/s12028-018-0614-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。